- Home
- » Tags
- » Benralizumab
Top View
- Tailored Therapy for Severe Asthma Francesco Menzella1*, Mirco Lusuardi2, Carla Galeone1 and Luigi Zucchi1
- Therapeutic Monoclonal Antibodies for Respiratory Diseases: Current Challenges & Perspectives March 31 - April 1, 2016
- INN Working Document 05.179 Update 2011
- Codes Drug Name J3262 Actemra (Tocilizumab) IV Only C9399, A4641
- A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
- Comparative Efficacy and Safety of Dupilumab And
- Pipeline: Respiratory, Inflammation & Autoimmunity (RIA) Inhaled Therapeutic Leadership; Spearheading Immunology Biologics
- (INN) for Biological and Biotechnological Substances
- Benralizumab, Dupilumab, Mepolizumab, Omalizumab and Reslizumab) for Severe Eosinophilic Asthma
- New Drugs: Briviact, Cinqair, Nuplazid, Taltz
- WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
- Medical Policy Update Bulletin
- Matching-Adjusted Indirect Comparison of Benralizumab Versus Interleukin-5 Inhibitors: Systematic Review
- New Initiators to Asthma Biologics: Apre/Post Analysis of Utilization Patterns, Total Cost of Care, and H.V
- Plaque Psoriasis Agents
- Targeting the IL-5 Pathway in Eosinophilic Asthma
- Reimbursement Criteria for Frequently Requested Drugs
- Cinqair (Reslizumab) Fasenra (Benralizumab) Nucala (Mepolizumab)
- Challenges and Opportunities for Predictive Toxicology of Monoclonal Antibodies
- Biological Therapy in Severe Asthma: a Gem Or a Jam Hesham Raafat
- Assessment of an Accessorized Pre-Filled Syringe for Home-Administered Benralizumab in Severe Asthma
- Psoriatic Arthritis Agents
- Monoclonal Antibody Therapy for Severe Asthma Information Paper for Primary Care Health Professionals
- Randomised Controlled Trials in Severe Asthma: Selection by Phenotype Or Stereotype
- Mechanisms, Diagnosis and Management of Eosinophilic Asthma
- Annual Report 2017 Morphosys AG Annual Report Product Pipeline Morphosys’S Product Pipeline (March 8, 2018)
- Benralizumab: a Unique IL-5 Inhibitor for Severe Asthma
- Single-Use Autoinjector Functionality and Reliability for At-Home Administration of Benralizumab for Patients with Severe Asthma: GRECO Trial Results
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Q1 2021 Presentation
- Respiratory Interleukins (Cinqair®, Fasenra®, & Nucala®)
- Benralizumab, Mepolizumab, and Reslizumab
- Self-Administered Medications List
- Highlights of FDA Activities – 11/1/17 – 11/30/17
- Cell-Mediated Immunity
- Esophagitis: Drugs Picture of Iron Pill Material in Biopsy TT’S Kodachrome 1St Page Folder Iron Medication Injury Medications/Drugs
- Prefilled Syringe/ Auto- Injector
- (INN) for Biological and Biotechnological Substances
- Benralizumab, Mepolizumab and Omalizumab for Treating Severe Asthma
- FASENRA (Benralizumab) Injection, for Subcutaneous Use Reduction in Corticosteroid Dosage: Do Not Discontinue Systemic Initial U.S
- Fasenra® (Benralizumab)
- Assessment of the Evolution of Cancer Treatment Therapies
- Caresource Pharmacy Policy Statement Marketplace Amevive (Alefacept)
- Tenofovir Alafenamide
- The Use of Intravenous Versus Subcutaneous Monoclonal
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances
- Monoclonal Antibodies in Type 2 Asthma: a Systematic Review and Network Meta- Analysis Ahmed Edris1, Silke De Feyter1,2, Tania Maes2, Guy Joos2 and Lies Lahousse1*
- Specialty Pharmacy Infusion Site of Care Benefit Preauthorization Drug List
- BILLING and CODING: COMPLEX DRUG ADMINISTRATION CODING (A58532) Links in PDF Documents Are Not Guaranteed to Work
- Risk of Infection Associated with Biological Agents Used for Autoimmune Inflammatory Diseases
- New and Effective Therapeutic Approaches Against Severe Asthma
- Antibodies to Watch in 2018
- Hypersensitivity Reactions to Biologics (Part I)